Treatment of Tuberculous Meningitis with HIV Co-infection in Patients Aged 19 Years or Younger

Managing tuberculous meningitis in children and adolescents is distinct from adult care, and the presence of HIV co-infection adds further clinical complexity that directly affects treatment decisions in this age group.

Clinical Scenario

This protocol applies to patients aged 19 years or younger with a diagnosis of tuberculous meningitis and confirmed or suspected HIV co-infection.

HIV co-infection is a key modifier in this population: current evidence carries a high certainty rating, and the recommendation for this group is considered weak — meaning the decision to follow this approach should be made on a case-by-case basis.

Treatment Approach

When a paradoxical reaction or immune reconstitution inflammatory syndrome arises in this setting, the approach centres on corticosteroid-based therapy — with adjustments to intensity and duration guided by the clinical response. The full protocol specifies the decision thresholds, sequencing, and criteria for escalation beyond standard corticosteroid management.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/S1473-3099(25)00364-0

For children and adolescents aged 19 years or younger with drug-susceptible tuberculous meningitis, WHO recently recommended that a 6-month regimen can be used instead of the 12-month standard regimen.

Is there HIV co-infection? High certainty of evidence, weak recommendation for use in people living with HIV so the decision to use should be made on a case-by-case basis.

Increase or prolong corticosteroids; in refractory cases consider other immunomodulating agents.

Expert opinion recommends using high-dose corticosteroids initially, tapering slowly according to symptom resolution.

View source ↗